Table 2. L. donovani isolates from India tested for their in vitro SbIII susceptibility and linked with clinical response.
| Isolates | Area | Drug response | LD score | IC50 (µM) | Index of SbIII resistance |
|---|---|---|---|---|---|
| Sensitive isolates: | |||||
| Dd8 (MHOM/IN/80/Dd8) | NA | NA | NA | 97 | 1 |
| 158-S1 | Muzaffarpur | Resistant area | 1+ | 69 | 0.712 |
| 155-S | Pard 111/3 | Sensitive area | 2+ | 84 | 0.867 |
| Resistant isolates: | |||||
| 151-R1 | Muzaffarpur | Resistant SAG | NA | 187 | 1.93 |
| 90-R2 | Muzaffarpur | Resistant area | 2+ | 194 | 2.2 |
| 77-R3 | Muzaffarpur | Resistant SAG | 1+ | 227 | 2.34 |
| 144-R4 | Muzaffarpur | Resistant | NA | 307 | 3.17 |
| amphotericin B | |||||
| 93-R5 | Ballia (BHU/NMW-17) | NA | 4+ | 308 | 3.18 |
| Lab raised mutant: | |||||
| Mt* | NA | NA | NA | >450 | > 4.64 |
*
Mt stands for laboratory raised mutant of L. donovani resistant to 450 µM potassium antimonyl tartarate hydrate (SbIII).